Fuxiang Shares released its 2026 interim report, achieving a turnaround from loss to profit. The company's total operating revenue was 888 million yuan, up 72.59 percent year-on-year. Net profit attributable to the parent company was 177 million yuan, an increase of 184 million yuan compared to the same period last year, marking three consecutive years of growth. Net cash inflow from operating activities was 69.4852 million yuan, up 540.77 percent year-on-year. The company's latest gross profit margin was 39.20 percent, achieving three consecutive quarters and three consecutive years of increase. ROE was 7.49 percent, an increase of 7.80 percentage points from the same period last year.
Jiangxi Fushine Pharmaceutical Co LtdCompany turned profitable with strong revenue and profit growth in interim report.
